Research Article
The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis
Table 2
Multivariate analysis of composite outcome in patients with AAV.
| | Univariate | Multivariate | Multivariate† | HR (95% CI) | value | HR (95% CI) | value | HR (95% CI) | value |
| Plasma suPAR levels (per 500 pg/mL increase) | 1.07 (1.03-1.12) | 0.002 | 1.05 (1.01-1.11) | 0.043 | 1.02 (0.96-1.08) | 0.563 | Age (year)§ | 1.04 (1.01-1.08) | 0.017 | 1.03 (0.99-1.07) | 0.128 | 1.05 (1.01-1.10) | 0.025 | Gender (male vs. female) | 1.02 (0.48-2.19) | 0.957 | 0.98 (0.46-2.11) | 0.961 | 0.74 (0.30-1.83) | 0.515 | Initial serum creatinine (per mg/dL) | 1.17 (1.06-1.30) | 0.003 | — | — | 1.22 (1.06-1.41) | 0.006 | Urinary protein (per g/24 h) | 0.93 (0.66-1.30) | 0.699 | — | — | 1.03 (0.71-1.49) | 0.879 |
|
|
Adjusted for age, gender; †adjusted for age, gender, initial serum creatinine, and urinary protein; §per 1 unit increase. Abbreviations: AAV: antineutrophil cytoplasmic antibody-associated vasculitis; HR: hazard ratio; CI: confidence interval. |